Werewolf Therapeutics, Inc. 8-K

What Happened

• On February 4, 2026, Werewolf Therapeutics, Inc. (HOWL) received a deficiency letter from the Nasdaq Listing Qualifications Department notifying the company that its common stock’s closing bid price had been below $1.00 for the last 30 consecutive business days, failing Nasdaq’s $1.00 minimum bid price requirement under Rule 5450(a)(1). The notice does not remove the stock from Nasdaq immediately.
• The company has an initial 180-calendar-day cure period (under Nasdaq Rule 5810(c)(3)(A)) to regain compliance, which expires on August 3, 2026. To cure, the stock must close at $1.00 or more for at least 10 consecutive business days during that period. If unsuccessful, a possible second 180‑day period may be available if the company transfers to the Nasdaq Capital Market and meets other listing standards; the company may appeal any delisting determination to a Hearings Panel.

Key Details

• Date of notice: February 4, 2026.
• Deficiency: Closing bid price below $1.00 for 30 consecutive business days (Minimum Bid Requirement).
• Initial cure window: 180 calendar days (until August 3, 2026); requires $1.00+ closing price for 10 consecutive business days.
• Next steps if not cured: possible transfer to Nasdaq Capital Market for a second 180‑day period (if other standards met) or a delisting notice that can be appealed to a Hearings Panel.

Why It Matters

• A failure to regain compliance could lead to delisting, which typically reduces liquidity and could negatively affect the stock’s marketability and value.
• The company’s shares remain listed for now, but investors should monitor the share price and company updates closely during the cure period.
• The filing confirms the risk but does not guarantee delisting; the company may regain compliance, transfer markets, or appeal — there is no assurance either outcome will occur.